Exploring the effect of epigenetic modifiers on developing insulin-secreting cells

Area of Science:

• Regenerative Medicine
• Endocrinology
• Epigenetics

Background:

• Diabetes mellitus is a global health concern with rising incidence.
• Current treatments fail to adequately manage diabetes comorbidities.
• Mesenchymal stromal cells (MSCs) offer potential for diabetes regenerative therapy.

Purpose of the Study:

• To improve MSC differentiation into glucose-sensitive, insulin-secreting cells using epigenetic modifiers.
• To investigate the effects of decitabine (Aza) and Vorinostat (SAHA) on MSC differentiation.
• To assess the functional capacity of modified MSCs to secrete insulin in response to glucose.

Main Methods:

• Human MSCs were treated with decitabine (Aza) or Vorinostat (SAHA) for 3 days.
• Cells underwent a multi-step differentiation protocol.
• Insulin secretion, gene expression (insulin, PDX-1, MafA, NKX6.1, GLUT2, glucokinase), and DNA methylation levels were analyzed.

Main Results:

• Aza treatment significantly increased intracellular insulin and PDX-1 expression.
• Aza-treated cells secreted insulin in response to high glucose, confirmed by ELISA.
• Gene expression analysis revealed induction of key genes for insulin production and glucose metabolism.
• SAHA showed some insulin upregulation but lacked glucose responsiveness.
• Aza treatment led to a significant decrease in global DNA methylation.

Conclusions:

• Decitabine (Aza) enhances MSC differentiation into functional, glucose-responsive insulin-secreting cells.
• Epigenetic modification with Aza represents a promising strategy for diabetes regenerative therapy.
• This approach may offer a novel regenerative solution for patients with diabetes.